A rare case of perimyocarditis induced by all-trans retinoic acid administration during induction treatment of acute promyelocytic leukemia

Authors

DOI:

https://doi.org/10.15386/mpr-1229

Keywords:

ATRA syndrome, drug induced myocarditis, acute promyelocytic leukemia

Abstract

Treatment by All-Trans Retinoic Acid (ATRA) combined with an Anthracycline Chemotherapy has been shown to improve disease-free survival in patients with Acute Promyelocytic Leukemia (APL). Although ATRA is generally well tolerated, occurrence of Retinoic Acid Syndrome (RAS) during the induction chemotherapy in some patients is recognized as a distinct complication and a potential life-threatening side effect.

Isolated myocarditis as a result of RAS related to ATRA administration is uncommon and has been rarely reported in the literature.

We report a very rare case of ATRA-induced perimyocarditis accompanied by hemodynamic compromise. There was complete resolution of the signs and symptoms of peri-myocarditis when ATRA was temporary suspended. Finally, ATRA was safely resumed.

Downloads

Published

2019-09-23

How to Cite

1.
Ben El Makki A, Mahtat EM, Kheyi J, Bouzelmat H, Chaib A. A rare case of perimyocarditis induced by all-trans retinoic acid administration during induction treatment of acute promyelocytic leukemia. Med Pharm Rep [Internet]. 2019 Sep. 23 [cited 2025 Oct. 28];92(4):418-20. Available from: https://medpharmareports.com/index.php/mpr/article/view/1229

Issue

Vol. 92 No. 4 (2019)

Section

Case Report

License

The authors are required to transfer the copyright of the published paper to the journal. This is done by agreeing to sign the Copyright Assignment Form. Whenever the case, authors are also required to send permissions to reproduce material (such as illustrations) from the copyright holder.

 Creative Commons License
The papers published in the journal are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.